Advertisement
LLY or PFE or ZTS
Which Stock Would AI Choose? Eli Lilly and Company (LLY) vs. Pfizer Inc. (PFE) vs. Zoetis Inc. (ZTS) Stock Comparison
Key Takeaways
- LLY shares have declined about 17% YTD amid sector volatility and competition in GLP-1 drugs (glucagon-like peptide-1 agonists, a class of medications for diabetes and obesity), despite strong revenue growth from Mounjaro and Zepbound.
- PFE leads with roughly 11-14% YTD gains, supported by non-COVID revenue stabilization, operational growth, and a high dividend yield around 6%, outperforming peers in recent market activity.
- ZTS trails with approximately 7% YTD returns, pressured by softer demand for key products like Librela and reduced veterinary visits, though Q4 revenue grew modestly.
- Recent momentum favors PFE for stability and value, while LLY offers growth potential from pipeline expansions like AI partnerships and acquisitions.
- All three operate in animal and human health sectors but differ in exposure: LLY and PFE in human pharma, ZTS focused on veterinary.
Introduction
This stock comparison examines LLY, PFE, and ZTS, three leaders in the healthcare sector spanning human pharmaceuticals and animal health. Investors seeking exposure to innovative therapies, dividend stability, or defensive growth amid market volatility may find value here. Recent weeks have highlighted contrasts in performance, with shifts driven by earnings, pipeline updates, and sector headwinds like pricing pressures and competition. This analysis aids traders evaluating relative performance, sentiment, and positioning for portfolio decisions in the current environment.
LLY Overview and Recent Performance
Eli Lilly and Company (LLY) is a global pharmaceutical firm renowned for diabetes, obesity, and oncology treatments, particularly GLP-1 drugs Mounjaro and Zepbound. In recent market activity, shares have fallen around 17% YTD and over 13% in the past month, trading near $887 after peaking above $1,100 earlier in 2026. Sentiment reflects competition from rivals like Novo Nordisk's oral weight-loss approvals and broader sector pullbacks, despite robust Q4 2025 revenue of $19.3 billion (up 43%). Positive catalysts include a $7.8 billion Centessa acquisition for neuroscience, up to $2.75 billion Insilico AI partnership, and eczema drug data, supporting long-term growth but contributing to valuation sensitivity at high multiples.
PFE Overview and Recent Performance
Pfizer Inc. (PFE) develops human medicines in oncology, vaccines, and rare diseases, with a diverse portfolio post-Seagen acquisition. Shares have risen about 11-14% YTD and 2-4% monthly, closing near $28, outperforming amid recovery from COVID peaks. Recent performance stems from 6% full-year operational revenue growth excluding COVID products, Q4 at $17.6 billion, and cost discipline. Key drivers include Abrysvo RSV vaccine, Prevnar, and Vyndaqel franchises, alongside a 6.2% dividend yield attracting income investors. Sentiment benefits from pipeline progress like HYMPAVZI reviews, though patent cliffs loom as risks.
ZTS Overview and Recent Performance
Zoetis Inc. (ZTS) leads animal health with vaccines, medicines, and diagnostics for pets and livestock. Shares are up modestly around 7% YTD but down 8-12% in recent months, trading near $116 in a 52-week range of $113-$172. Performance reflects U.S. companion animal softness, including fewer vet visits and Librela (osteoarthritis drug) demand issues amid safety concerns, offsetting 3% Q4 revenue growth to $2.4 billion. Guidance for 2026 revenue of $9.83-$10.03 billion and EPS $7.00-$7.10 provides stability, with growth in parasiticide and dermatology segments supporting resilience in the veterinary niche.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies. With over 351 AI bots in total, only 25 earn a spot in this dynamic section based on real-time analysis of profitability, consistency, and adaptation to prevailing market conditions like volatility levels (low, medium, high). These bots employ varied styles—from price action and pattern recognition to sector-specific approaches—spanning timeframes like intraday to swing trades, delivering signals for copy trading. Past highlights include annualized returns up to 171% over 30 days with 100% win rates on select agents, and averages exceeding 100% in high-growth sectors. Explore Trending AI Robots to identify tools suited to current trends.
Head-to-Head Comparison
LLY, PFE, and ZTS share healthcare exposure but diverge in models: LLY chases high-growth via GLP-1 dominance (83% gross margins), PFE balances breadth with dividends (6% yield, lower P/E), and ZTS niches in veterinary stability. Growth drivers contrast—LLY's 45% revenue surge vs. PFE's 6% non-COVID and ZTS's 3%—with PFE showing strongest recent momentum. Risks include LLY's competition and valuation (high P/E), PFE's patent losses, and ZTS's product-specific demand. Sector-wise, human pharma faces reimbursement pressures, while animal health offers diversification. Sentiment tilts to PFE for relative stability.
Tickeron AI Verdict
Tickeron’s AI currently favors PFE due to superior trend consistency, YTD outperformance, dividend support, and lower relative risk in stabilizing non-COVID operations. While LLY holds stronger catalysts like acquisitions and AI collaborations, its volatility suits aggressive positioning; ZTS lags on momentum. Probabilistic edge leans to PFE for balanced returns amid uncertainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LLY’s FA Score shows that 2 FA rating(s) are green whilePFE’s FA Score has 2 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- LLY’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 2 green, 3 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LLY’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 3 bullish TA indicator(s), and ZTS’s TA Score reflects 4 bullish TA indicator(s).
- LLY’s TA Score: 5 bullish, 3 bearish.
- PFE’s TA Score: 3 bullish, 4 bearish.
- ZTS’s TA Score: 4 bullish, 6 bearish.
Price Growth
LLY (@Pharmaceuticals: Major) experienced а +2.10% price change this week, while PFE (@Pharmaceuticals: Major) price change was -3.88% , and ZTS (@Pharmaceuticals: Generic) price fluctuated +1.74% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.87%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +6.57%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.55%. For the same industry, the average monthly price growth was +3.94%, and the average quarterly price growth was -0.03%.
Reported Earning Dates
LLY is expected to report earnings on Apr 30, 2026.
PFE is expected to report earnings on May 05, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.87% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Pharmaceuticals: Generic (+3.55% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| LLY | PFE | ZTS | |
| Capitalization | 853B | 155B | 50.5B |
| EBITDA | 31.7B | 16.8B | 4.07B |
| Gain YTD | -10.970 | 11.148 | -4.226 |
| P/E Ratio | 41.62 | 20.01 | 19.93 |
| Revenue | 65.2B | 62.6B | 9.47B |
| Total Cash | 7.27B | 13.6B | 2.31B |
| Total Debt | 42.5B | 64B | 9.24B |
LLY | PFE | ZTS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 74 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 33 Fair valued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 19 | 99 | 100 | |
SMR RATING 1..100 | 13 | 73 | 16 | |
PRICE GROWTH RATING 1..100 | 55 | 28 | 61 | |
P/E GROWTH RATING 1..100 | 88 | 35 | 85 | |
SEASONALITY SCORE 1..100 | 50 | 12 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZTS's Valuation (30) in the Pharmaceuticals Generic industry is in the same range as PFE (33) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for LLY (68) in the Pharmaceuticals Major industry. This means that ZTS's stock grew similarly to PFE’s and somewhat faster than LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (19) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (99) in the Pharmaceuticals Major industry, and is significantly better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that LLY's stock grew significantly faster than PFE’s and significantly faster than ZTS’s over the last 12 months.
LLY's SMR Rating (13) in the Pharmaceuticals Major industry is in the same range as ZTS (16) in the Pharmaceuticals Generic industry, and is somewhat better than the same rating for PFE (73) in the Pharmaceuticals Major industry. This means that LLY's stock grew similarly to ZTS’s and somewhat faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (28) in the Pharmaceuticals Major industry is in the same range as LLY (55) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for ZTS (61) in the Pharmaceuticals Generic industry. This means that PFE's stock grew similarly to LLY’s and somewhat faster than ZTS’s over the last 12 months.
PFE's P/E Growth Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZTS (85) in the Pharmaceuticals Generic industry, and is somewhat better than the same rating for LLY (88) in the Pharmaceuticals Major industry. This means that PFE's stock grew somewhat faster than ZTS’s and somewhat faster than LLY’s over the last 12 months.
| LLY | PFE | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 74% | N/A | 1 day ago 55% |
| Stochastic ODDS (%) | 1 day ago 59% | 1 day ago 61% | 1 day ago 62% |
| Momentum ODDS (%) | 1 day ago 65% | 1 day ago 49% | 1 day ago 52% |
| MACD ODDS (%) | 1 day ago 62% | 1 day ago 62% | 1 day ago 69% |
| TrendWeek ODDS (%) | 1 day ago 70% | 1 day ago 58% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 51% | 1 day ago 63% |
| Advances ODDS (%) | 1 day ago 71% | 9 days ago 56% | 1 day ago 52% |
| Declines ODDS (%) | 4 days ago 54% | 3 days ago 57% | 14 days ago 58% |
| BollingerBands ODDS (%) | 1 day ago 72% | 1 day ago 52% | 1 day ago 59% |
| Aroon ODDS (%) | 1 day ago 56% | 1 day ago 51% | 1 day ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| STRK.X | 0.033933 | 0.000958 | +2.91% |
| Starknet cryptocurrency | |||
| GK | 25.08 | 0.20 | +0.80% |
| AdvisorShares Gerber Kawasaki ETF | |||
| TOLZ | 61.71 | 0.32 | +0.52% |
| ProShares DJ Brookfield Global Infras | |||
| PID | 22.69 | -0.11 | -0.48% |
| Invesco International Div Achiev ETF | |||
| LMBO | 18.04 | -0.33 | -1.78% |
| Direxion Daily Crypto Industry Bull2XETF | |||
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with MRK. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then MRK could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been closely correlated with MRK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if PFE jumps, then MRK could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.91% | ||
| MRK - PFE | 67% Closely correlated | -0.41% | ||
| BMY - PFE | 67% Closely correlated | +0.46% | ||
| BIIB - PFE | 64% Loosely correlated | -1.55% | ||
| AMGN - PFE | 61% Loosely correlated | +1.66% | ||
| NVS - PFE | 56% Loosely correlated | +0.41% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +0.20% | ||
| ELAN - ZTS | 52% Loosely correlated | -0.59% | ||
| VTRS - ZTS | 44% Loosely correlated | +0.26% | ||
| PRGO - ZTS | 41% Loosely correlated | -2.12% | ||
| PAHC - ZTS | 39% Loosely correlated | +0.78% | ||
| HLN - ZTS | 39% Loosely correlated | +0.40% | ||
More | ||||